Literature DB >> 12673364

TP53 and mutations in human cancer.

Katarzyna Szymańska1, Pierre Hainaut.   

Abstract

TP53 is the most frequently mutated gene in human cancer, with a predominance of missense mutations scattered over 200 codons. In many cancers, specific mutation patterns can be identified, which are shaped by site-specific mutagenesis and by biological selection. In tobacco-related cancers (lung, head and neck), organ-specific patterns are observed, with many mutations compatible with the ones experimentally induced by tobacco carcinogens. In several other cancers, such as squamous cell carcinoma of the oesophagus or hepatocellular carcinoma (HCC), mutation patterns show geographic variations between regions of high and low incidence, suggesting a role for region-specific risk factors. HCC from high-incidence regions showing also a high prevalence of a specific Ser-249 TP53 mutation is one of the most striking examples of a mutagen fingerprint. All such assessments are useful to generate clues on the mutagenic mechanisms involved in human cancer. Moreover, it has been shown that DNA retrieved from plasma can be successfully used for detection of TP53 mutations, which gives hope for earlier more accurate detection of human cancers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12673364     DOI: 035001231

Source DB:  PubMed          Journal:  Acta Biochim Pol        ISSN: 0001-527X            Impact factor:   2.149


  18 in total

1.  Varying responses of human cells with discrepant p53 activity to ionizing radiation and heat shock exposure.

Authors:  S V Tokalov; S Pieck; H O Gutzeit
Journal:  Cell Prolif       Date:  2007-02       Impact factor: 6.831

2.  Association between the P53 codon 72 polymorphism and nasopharyngeal cancer risk.

Authors:  Kemin Cai; Yu Wang; Xiaojun Zhao; Xueli Bao
Journal:  Tumour Biol       Date:  2013-10-11

3.  Specific mutation screening of TP53 gene by low-density DNA microarray.

Authors:  Angélica Rangel-López; Alfonso Méndez-Tenorio; Kenneth L Beattie; Rogelio Maldonado; Patricia Mendoza; Guelaguetza Vázquez; Carlos Pérez-Plasencia; Martha Sánchez; Guillermo Navarro; Mauricio Salcedo
Journal:  Nanotechnol Sci Appl       Date:  2009-01-20

4.  Meta-signature of mutated genes in gallbladder cancer: evidence based high throughput screening assays.

Authors:  Kai Qu; Xing Zhang; Ruixia Cui; Chang Liu
Journal:  Ann Transl Med       Date:  2016-06

5.  Co-targeting p53-R249S and CDK4 synergistically suppresses survival of hepatocellular carcinoma cells.

Authors:  Huai Wang; Peng Liao; Shelya X Zeng; Hua Lu
Journal:  Cancer Biol Ther       Date:  2019-11-21       Impact factor: 4.742

6.  Clinical implication of 14-3-3 epsilon expression in gastric cancer.

Authors:  Mariana Ferreira Leal; Danielle Queiroz Calcagno; Sâmia Demachki; Paulo Pimentel Assumpção; Roger Chammas; Rommel Rodríguez Burbano; Marília de Arruda Cardoso Smith
Journal:  World J Gastroenterol       Date:  2012-04-07       Impact factor: 5.742

Review 7.  p53--a Jack of all trades but master of none.

Authors:  Melissa R Junttila; Gerard I Evan
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

8.  Concurrent targeting of eicosanoid receptor 1/eicosanoid receptor 4 receptors and COX-2 induces synergistic apoptosis in Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus associated non-Hodgkin lymphoma cell lines.

Authors:  Arun George Paul; Bala Chandran; Neelam Sharma-Walia
Journal:  Transl Res       Date:  2013-03-20       Impact factor: 7.012

9.  hTERT, MYC and TP53 deregulation in gastric preneoplastic lesions.

Authors:  Tanielly Cristina Raiol Silva; Mariana Ferreira Leal; Danielle Queiroz Calcagno; Carolina Rosal Teixeira de Souza; André Salim Khayat; Ney Pereira Carneiro dos Santos; Raquel Carvalho Montenegro; Silvia Helena Barem Rabenhorst; Mayara Quaresma Nascimento; Paulo Pimentel Assumpção; Marília de Arruda Cardoso Smith; Rommel Rodríguez Burbano
Journal:  BMC Gastroenterol       Date:  2012-07-06       Impact factor: 3.067

10.  Interrelationship between TP53 gene deletion, protein expression and chromosome 17 aneusomy in gastric adenocarcinoma.

Authors:  André S Khayat; Adriana C Guimarães; Danielle Q Calcagno; Aline D Seabra; Eleonidas M Lima; Mariana F Leal; Mário H G Faria; Silvia H B Rabenhorst; Paulo P Assumpção; Samia Demachki; Marília A C Smith; Rommel R Burbano
Journal:  BMC Gastroenterol       Date:  2009-07-20       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.